What is the current valuation of the US Blepharoplasty Market?

The US Blepharoplasty Market was valued at 810.0 USD Million in 2024. Read More

What is the projected market valuation for the US Blepharoplasty Market in 2035?

The market is projected to reach 1288.8 USD Million by 2035. Read More

What is the expected CAGR for the US Blepharoplasty Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 4.31%. Read More

What are the main procedure types in the US Blepharoplasty Market?

Main procedure types include Upper Blepharoplasty, Lower Blepharoplasty, Double Eyelid Surgery, and Transconjunctival Blepharoplasty. Read More

How does the market segment by demographics appear?

The demographic segments include Age Group, Gender, Income Level, and Ethnicity, with valuations ranging from 180.0 to 400.0 USD Million. Read More

What surgical techniques are utilized in the US Blepharoplasty Market?

Surgical techniques include Traditional Surgery, Laser Surgery, Endoscopic Surgery, and Non-Surgical Options. Read More

What are the primary indications for blepharoplasty procedures?

Indications include Cosmetic Enhancement, Functional Impairment, and Reconstructive Surgery. Read More

How is the patient type segmented in the US Blepharoplasty Market?

Patient types are segmented into First-Time Patients, Repeat Patients, and Referral Patients, with valuations from 243.0 to 520.0 USD Million. Read More

What does the market outlook suggest for the US Blepharoplasty Market in the coming years?

The market outlook suggests steady growth, with a projected increase in valuation and a consistent demand for various blepharoplasty procedures. Read More

US Blepharoplasty Market

Q: Which companies are considered key players in the US Blepharoplasty Market?

Key players include Allergan, Revance Therapeutics, Medytox, Hugel, Galderma, Sientra, and AptarGroup. Read More

ID: MRFR/HC/14652-HCR

128 Pages

Rahul Gotadki

Last Updated: April 06, 2026

US Blepharoplasty Market Research Report Information By Type (Upper Eyelid Blepharoplasty, Lower Eyelid Blepharoplasty, and Combination Eyelid Surgery), By Gender (Female and Male), By Service Provider (Hospitals, Clinics, and Ambulatory Surgical Centre) –Market Forecast Till 2035

US Blepharoplasty Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)4.31%

2024 Market Size$ 810 Million

2025 Market Size$ 847.8 Million

2035 Market Size$ 1,288.8 Million

Key Players

Allergan

Revance Therapeutics

Medytox

Hugel

Galderma

Sientra

Trends

Rise of Minimally Invasive Techniques
Influence of Social Media
Aging Population Driving Demand

Opportunities

Regulatory Support and Safety Standards
Growing Interest in Anti-Aging Solutions
Increased Awareness of Aesthetic Procedures

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Procedure Type (USD Million)
  1. 4.1.1 Upper Blepharoplasty
  2. 4.1.2 Lower Blepharoplasty
  3. 4.1.3 Double Eyelid Surgery
  4. 4.1.4 Transconjunctival Blepharoplasty
2. 4.2 Healthcare, BY Demographics (USD Million)
  1. 4.2.1 Age Group
  2. 4.2.2 Gender
  3. 4.2.3 Income Level
  4. 4.2.4 Ethnicity
3. 4.3 Healthcare, BY Surgical Technique (USD Million)
  1. 4.3.1 Traditional Surgery
  2. 4.3.2 Laser Surgery
  3. 4.3.3 Endoscopic Surgery
  4. 4.3.4 Non-Surgical Options
4. 4.4 Healthcare, BY Indication (USD Million)
  1. 4.4.1 Cosmetic Enhancement
  2. 4.4.2 Functional Impairment
  3. 4.4.3 Reconstructive Surgery
5. 4.5 Healthcare, BY Patient Type (USD Million)
  1. 4.5.1 First-Time Patients
  2. 4.5.2 Repeat Patients
  3. 4.5.3 Referral Patients
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Allergan (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Revance Therapeutics (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Medytox (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Hugel (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Galderma (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sientra (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AptarGroup (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Medytox (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Hugel (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY PROCEDURE TYPE
3. 6.3 US MARKET ANALYSIS BY DEMOGRAPHICS
4. 6.4 US MARKET ANALYSIS BY SURGICAL TECHNIQUE
5. 6.5 US MARKET ANALYSIS BY INDICATION
6. 6.6 US MARKET ANALYSIS BY PATIENT TYPE
7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF HEALTHCARE
10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
13. 6.13 HEALTHCARE, BY PROCEDURE TYPE, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY PROCEDURE TYPE, 2024 TO 2035 (USD Million)
15. 6.15 HEALTHCARE, BY DEMOGRAPHICS, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY DEMOGRAPHICS, 2024 TO 2035 (USD Million)
17. 6.17 HEALTHCARE, BY SURGICAL TECHNIQUE, 2024 (% SHARE)
18. 6.18 HEALTHCARE, BY SURGICAL TECHNIQUE, 2024 TO 2035 (USD Million)
19. 6.19 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
20. 6.20 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Million)
21. 6.21 HEALTHCARE, BY PATIENT TYPE, 2024 (% SHARE)
22. 6.22 HEALTHCARE, BY PATIENT TYPE, 2024 TO 2035 (USD Million)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY PROCEDURE TYPE, 2026-2035 (USD Million)
  2. 7.2.2 BY DEMOGRAPHICS, 2026-2035 (USD Million)
  3. 7.2.3 BY SURGICAL TECHNIQUE, 2026-2035 (USD Million)
  4. 7.2.4 BY INDICATION, 2026-2035 (USD Million)
  5. 7.2.5 BY PATIENT TYPE, 2026-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US US Blepharoplasty Market Segmentation

US Blepharoplasty Market By Procedure Type (USD Million, 2026-2035)

Upper Blepharoplasty
Lower Blepharoplasty
Double Eyelid Surgery
Transconjunctival Blepharoplasty

US Blepharoplasty Market By Demographics (USD Million, 2026-2035)

Age Group
Gender
Income Level
Ethnicity

US Blepharoplasty Market By Surgical Technique (USD Million, 2026-2035)

Traditional Surgery
Laser Surgery
Endoscopic Surgery
Non-Surgical Options

US Blepharoplasty Market By Indication (USD Million, 2026-2035)

Cosmetic Enhancement
Functional Impairment
Reconstructive Surgery

US Blepharoplasty Market By Patient Type (USD Million, 2026-2035)

First-Time Patients
Repeat Patients
Referral Patients

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”